Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRiTE in Newly Diagnosed or Recurrent Glioblastoma
NCT04903795Phase 1Recruiting
- Start
- Aug 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in glioblastoma (GBM). Primary endpoint: Dose-limiting toxicity at 28 days. Started Aug 2026; status: recruiting.
02
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04903795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04903795.